C. Mills
Thank but a right. part to slide, to All could of our I'm give statement Matt, you, it's that here. get imagine going any better forward-looking it the hard shot than presentation and
on We today. with have some new call us people our
be So a a history little we're whole over the of just at going happy earnings obviously, out. to But will a the I be of stuff bit about. us chance background go the through release Matt components. we'll exciting was some see And to financial through of question. we've take to but you your that we'll the taking put then to talk got be got lot hope that. going and company, of end, the
without our can so mission that patients medicine Elutia, thrive compromise. So humanizing
rate company stage platforms. a commercial product a are run revenue We growing $XX now on of million and the backs with proprietary X
Our is used implantable product reconstruction. breast line, which which product used electronic in platform, devices pacemakers and CanGaroo SimpliDerm and our is to protect
that devices solve we implantable excitingly, use technology. are and currently problems we But pioneering very Biomatrix addressed serious are state-of-the-art that drug-eluting to very the not by the with
jump for FDA expect pacemakers us biologic within that coming disruption. drug-eluting market I'll device this, but over And protection of clearance is we Importantly, ability right that up our CanGarooRM now. in the June go to really million a right first gives $XXX into
it. let's jump So into
Okay.
revenue XX% it for sales the star exceptional but standpoint from for real another a quarter, million. was highlight So we business in the standout at of $X.X this the million us quarter, quarter. in quite a run first SimpliDerm $XX first surging revenue with a one puts rate had really from quarter, a the was about
quarter this A for clearance are obviously, of eyes background. line, June product all that on and expect CanGaroo of we little up. then coming now bit our And in
So natural things, a component, drug-eluting what those adding by that have matrices biologic, the as a we and to able a is pharmaceutical well and are regenerative do we taking do are products that combining at that component. we biological X by create this we pharmaceutical pioneering company payload to as
So about technology it's is active also are really able being healthy best idea implant And postoperative such an really of both able the infections. agents worlds, as own regenerates brings things, tissue that in us. that impact what but to incorporates that and we're to the excited deliver have your pharmaceutical
that said, of up. CanGarooRM this, next first coming and our CanGaroo which line one on with let's application So the product jump is into our
this a -- in the pacemaker line in space. and CID basically or used a is defibrillator product So the is CanGaroo CanGaroo is product that's internal
pacemakers each year, there placed. are about that XXX,XXX are So
at There's XX% in in pacemaker XX%. the Medtronic and a distant bit share really players has between significant XX% fourth of only and Biotronic, at about each XX% field. with the space, Boston that other a X Abbott market then divided Scientific
able And to which not compete actually are perform facilitate implantable marketplace make patients the help. in instead they're to so that but the intended is we in and pacemakers this these with, better
we can a somebody for This why receiving CanGaroo CanGarooRM? like need pacemaker. or do look So it is what
lead can some so patients it. on the the the identifying you things see off there, wire have in thin space, the that and problem like of even And their skin, of these comorbidities left the and problems coming and physician pacemaker no you picture
look the idea underneath place and that pacemaker closely, cascade might with you this pacemaker. this skin really patient If serial thinner skin the of events. able sets a But a directly having be number you see off on of to
them of is And so one migration.
the placed. actual you can and the see over pacemaker to the where towards was picture can And pit. this see So that rotating arm is the laterally pacemaker was you incision an arrow right, the next
pacemaker against events and the can is the leads the that But in can have pacemaker skin, And tension those starts you a have erosion, and you and pulling and that thing lead which to dislodge. move over. that is micromotion happen can on problems. next lead of is series motion picture leads that the see could another can can One here the
can Well, erosion of third picture if the body. big over, of you're literally his so outside be. problem And from sure you see patient not dangling a pacemakers this how can pacemaker
failure obviously sustainable that's the placed ventricle. That's to have to somebody room back which pace. fixed. be that's lead right that In those -- are obviously, can and have picture, into that meantime, have the pulling that not operating leads, And supposed to, going go to on a firmly to in the it's
this And of then lastly, it's idea infection.
significant as infection be and putting or at who you're pacemakers. a need catastrophic patient, a event like for that smoking anytime particularly comorbidities in that into long-term type risk obesity really a postoperative So can have device diabetes, you're such a things or implantable those patients X
of that with at problem generally device failure is you host pacemakers. most the pacemakers the I've Pacemakers themselves the interface, common that don't most shown address to fail So type see occur just here. don't break, very like failures often. with we're trying spontaneously They
what that's And we're actually and trying to CanGaroo with CanGarooRM. address
into right rifampin was minocycline. place acquired around elutes was this playing product entrant product originally it real a approved, was we're that synthetic a And that antibiotic that off you putting as these the called their inside introduced was shortly called a that the with first TYRX was fully in idea the now TYRX it implantation different procedure thing resonated something of by And is protection by after in. dissolves the Medtronic. having product it dissolves, TYRX are space this and pacemaker and Medtronic that TYRX, company The pacemaker and polymer here that that as of got a electrophysiologists ultimately,
think antibiotics matrix. product. do this it's And market, since million they do TYRX we That's in. year in to a think a in was the by for market and space synthetic rifampin million, acquired market they moving instead by having really but of and created better can more we to have a this we biologic regenerative this $XXX about about minocycline, with And a pouch million powerful was one where We there that's market have Medtronic back taken over $XXX we disrupt none. a XXXX they natural $XXX estimate that can
benefits and getting and that's of to skin these all antibiotic thin of in things. having other you're but some address illusion, inflammation complications the of all and fibrosis So and of the able one migration
did said biologic they majority market to when of electrophysiologists survey we're went some part we an and move TYRX envelope them came a talked using out all fact, when overwhelming as to of would CanGarooRM that of a we their business In it or out. cases, XX% their like
market competitive it. in a product this so million we $XXX But only and this it about we and getting as actually And it one excited with we're approved super view superior player. as product, not launching a view
in update on said, that towards you So an FDA where our are path let's clearance. we give
FDA. product through December combination pretty It's a our filing review significant submitted So we year. this with of gone in
of interactions been very date to our All have positive.
final working now through, say, are We I the details. very would
close details expect to right then all that out be expect we those would we decision month. And And stand put fully on to favorable now, in FDA for track We June. an us a that decision. within of where the
we've this market. take to that, got After to product
base X little commercialization customers and first just so We first using centers are tier. second an groups customers a those And -- product. our bit our are our as of that That our really strategy and of first tier currently following approval. CanGaroo, on see those overview
centers CanGaroo And into fairly fruit. now we of We and opportunity going on sales flipping low would hanging after have that XXX CanGarooRM revenue there about see have provide right think those we existing currently that centers million $XX us as formulary.
currently those we that around putting behind $XX TYRX, there. a business but of Right are are that. that, they're Abbott Boston though, million electrophysiologists and about There's using TYRX Medtronic a estimate pacemakers, product
of and and us about So for revenue first -- after you first, those that's that's really X $XXX million put low-hanging fruit, fairly our think there's opportunity we tier to go approach. together,
on we And benefit their product, those are we and we that, in CanGarooRM. superior now right using are Medtronic and TYRX think have significant over aren't that to there's a think so them do for those an customers. Beyond after the also, currently sidelines procedures, to envelope use that go we going switch
started are have at in site we the our in a of scaling Georgia year. the manufacturing As launch production of -- second in such, Atlanta, preparation our we half
CanGarooRM where our with and line. CanGaroo that's So product are we
us would for this impossible go be to it through almost Next, call.
mentioned As performance our product. the Jo SimpliDerm standout of
reconstruction, breast of of form women, invasive and unfortunately, a cancer there bit the that of develop their are little a as Biomatrix some in will of So breast XX% about role lifetime. background,
to leads States, XX% United that actually to mastectomies. about will each year, somewhere mastectomies the XXX,XXX between XX% of those In bilateral be
the put $X.X looking for improvement of that really innovation. million all States is addressable United market hasn't we're what market in And whole that's a alone And that market. together, lot do. breast You that is reconstruction about a the a seen to really
where space, space, here stale. can but had outcome. protection the Again, pacemaker see the it's And gotten think it. some we good frankly, we've next-generation and a technology, disrupt products to in just there breast opportunity provide executing reconstruction in with same little along like we're patients second-generation come with and really the in the it's We superior we and go
a show so we you is with getting about Let is what is SimpliDerm little well why in questions it the me performing bit here some that mean SimpliDerm, marketplace.
a looking a here, of surgeon for with it starts the they're the a Sort sees, bit of and take conforming -- you first flexible out product. first through thing but store
an the drape it's going feel. around or how that of services SimpliDerm pre Imagine the and complex well to a that towards breast It's comply fit curved surface. expander and a hydrated. It's You look, over surface implant right con with implant. see able
is that minus a directly the sterility assurance It's X. comes up the means to it able XX open level field. sterilized terminally the onto of to surgeon -- operating in it So already
surgeon the one able this other directly And biologic so any used the to fully is field in it tool and product the to surgical, is other surgical up compatible if a right on use product. away, this surgical like open any procedure,
and proprietary therefore, were the And in that one developing processing of responses. the different marker to seen so making process that's this the minimize kinds a most methodology doing were [indiscernible] potential was things product, were for inflammation minimize we develop this of inflammatory trying inflammatory were we -- would important product, as all we response of we
the be mean? that Look looking you at from that hours and could see that's depict types okay, where look it cells. one that marker hours The a say, What does are. in different body on would right, the you kind substances. of if so this of are we CDXX the Well, histology CDXX. This use stained to macrophages is foreign attacking inflammatory to happens for at be interesting.
foreign that that body are versus showing develop. is these there and receiving that so receiving processing proprietary significantly Alder is this are what inflammation and that X together, the response And comes from methodology and you animals is put those things that SimpliDerm less that we in
So it. and where acellular called patient that looking you I syndrome with what's all sort and got the slide is at this might publication do care? of you -- breast it the paste I at This Why is look go a "Okay, say, all at matters. dermal next up -- level, to Randy, Well, this matrix. done is because of red
change back unacceptable, doing And so they sometimes have and so have it to patient that and doing can for frankly, much out. the up can go the these in when that XX% to outs, response procedure, a of a have inflammation inflammatory postoperative patients you're have change significant time, becomes when and be the to painful and breast reconstruction very you're
where is it a this led back able was the Syndrome reconstruction patient go was procedure, in matrix and acellular out for syndrome used changed patient, study this away. another had go to done red SimpliDerm room. to to the was intolerable They Breast it dermal for Red the into So was that the breast case operating
and less direct the response, inflammatory that response is less immunogenic causes ultimately, of less a cellular reduced for a result This outcome -- patient. a that better product inflammatory
everyone that's And in what behind then is for of pay science why us. reconstruction -- off it could excited commercially see that's SimpliDerm the about So these you the sort breast procedures. so
through in trained highly X internal proprietary for SimpliDerm So is SimpliDerm distributors. One XX% ways. the absolutely stellar distribute our quarter We quarter. again growing
it also, be would Sientra, recently I to year, partnership by with And disruption acquired with in beneficial through I a remains of, that the growth went Tiger some first they XX% We signed nonexclusive They say, despite is this -- seen. last sort quarter. were could that would Sientra. say disruption be still of
it. of that network are But we own just have distributors our crushing
product So reconstruction we product serious company CanGaroo companies. and are super this breast SimpliDerm is how about both starting into our going really everything in it's our and real commercial show space, what's evolving excited on to a with the in about
of CFO, for So minute with through stop that, X will allow Matt. and some the Ferguson, walk you or Matt to a I financials, our
